By: Grace Huff At the Norman Fixel Institute for Neurological Diseases, research fellow A. Enrique Martinez-Nunez, M.D., Movement Disorders neurologist and ALS research fellow, is working to answer one of the most urgent questions in neurodegenerative disease: why does ALS progress differently from one patient to another?…
By: Mallory Bachmann The Amyotrophic Lateral Sclerosis (ALS) Clinic at the Norman Fixel Institute for Neurological Diseases at UF Health has been officially recognized as a Center of Excellence by the ALS Association. This designation reflects the clinic’s adherence to the program’s standards, including…
By: Grace Huff First-ever Napier ALS Fellow begins July 1 at the Norman Fixel Institute for Neurological Diseases Coach Napier with Fixel Institute Fellows A. Enrique Martinez, MD, Rachel Burke, MD, Patricia Graese, MD, Dorian Kusyk, MD, and Amanda Currie, MD. Coach Napier with Fixel Institute Executive Director, Michael…
By: Grace Huff This post is dedicated to ALS Awareness Month, a time to honor the strength of those living with ALS and to recognize the critical work being done to improve care and accelerate research. By spotlighting this complex disease, we aim to foster greater understanding, reduce stigma, and…
Drs. James Wymer and Michael Okun contributed to annual NEJM Group publication.
Join us for ALS Awareness Month and explore ways we can make a difference in the lives of those affected by this complex neurological disorder.
UF neuroscientists collaborate on international study revealing a potential therapeutic target for ALS, FTD linked to TDP-43.
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
UF was the No. 2 enroller of patients for multisite ALS trial.
